Immunization

• EMA withdrawal · 2019-04-02
  EMA Withdrawn: Silgard (human papillomavirus type 6 L1 protein;human papillomavirus type 11 L1 protein;human papillomavirus type 16 L1 protein;human papillomavirus type 18 L1 protein) — Merck Sharp Dohme Ltd

  EMA withdrawn the HPV vaccine Silgard (HPV 6/11/16/18 L1 proteins) from the market.

• EMA withdrawal · 2013-08-23
  EMA Lapsed: Infanrix Penta (Diphtheria toxoid;tetanus toxoid;Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin);poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain));hepatitis B surface antigen) — GlaxoSmithKline Biologicals S.A.

  EMA status indicates Infanrix Penta is lapsed, with the product no longer active in this market.

• EMA withdrawal · 2011-06-30
  EMA Withdrawn: Humenza (split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs.) — Sanofi Pasteur S.A.

  EMA has withdrawn the Humenza influenza vaccine from the market.

• EMA withdrawal · 2008-09-10
  EMA Withdrawn: Quintanrix (Diphtheria toxoid;tetanus toxoid;inactivated Bordetella pertussis;hepatitis B surface antigen (rDNA);Haemophilus influenzae type b polysaccharide) — GlaxoSmithKline Biologicals S.A.

  Quintanrix has been withdrawn from the market by GlaxoSmithKline Biologicals S.A., with the status indicating withdrawal for its diphtheria,…